Aim: To report glycemic control and pregnancy outcome in pregnant women with type 1 diabetes on insulin degludec. Methods: Twenty-two women with type 1 diabetes on degludec from conception to delivery between 2014 and 2018 were compared with 51 pregnant women with type 1 diabetes on glargine. Results: Baseline characteristics were comparable, however HbA1c was higher at median 9 (range 5–19) weeks in women on degludec compared to women on glargine (6.9% (5.7–8.7); (52 (39–72) mmol/mol) versus 6.4% (5.1–10.1); (46 (32–87) mmol/mol), p = 0.04). HbA1c was similar in late pregnancy (6.3% (5.6–7.1); (45 (38–54) mmol/mol) versus 6.1% (5.2–9.0); (43 (33–75) mmol/mol), p = 0.28). The prevalence of severe hypoglycemia was 3 (14%) versus 6 (12%), p = 1.00 during pregnancy and 0 versus 1, p = 1.00 during hospital admittance after delivery. Most women on degludec used one daily injection in early (20 (91%) versus 25 (49%), p = 0.001) and late pregnancy (21 (96%) versus 19 (37%), p < 0.001). No significant differences in obstetrical and neonatal outcomes were found between the groups. Maternal hospital admittance after delivery was 2 (1–5) versus 3 (2–11) days (p = 0.004). Conclusions: Glycemic control in late pregnancy, severe hypoglycemia during and immediately after pregnancy as well as pregnancy outcome were comparable in women on degludec or glargine. Degludec initiated preconceptionally may be continued in pregnancy.